Board of Directors

Sam Shrivastava


Sam Shrivastava is an accomplished biotech entrepreneur, business strategist, and investor. In 2016, Sam founded Venn Therapeutics, a highly innovative drug discovery incubator. Under his visionary leadership as Chairman and CEO, a team of leading clinical immunotherapists and scientific inventors are developing a portfolio of novel, best-in-class integrin antibodies that are translating today’s most promising and innovative breakthroughs in cancer research into tomorrow’s life-saving treatments.

Mr. Shrivastava is also the founder and Chairman of Ibis Therapeutics, which uses artificial intelligence and machine learning to build small-molecule drugs and repurpose existing drugs. Ibis is currently working with a team of immunologists and virologists exclusively focused on COVID-19.

Mr. Shrivastava began his career in banking before founding his first company, Blackbird BioFinance, an immuno-oncology company focused on lung cancer. Blackbird was sold 14 months later to Cellular Biomedicine Group Inc. (NASDAQ: CBMG).

In all his endeavors, Mr. Shrivastava is committed to improving patient health outcomes and creating shareholder value through rigorous target selection, clinical and preclinical studies, antibody production management, and small molecule synthesis execution.

Mr. Shrivastava is the co-inventor on two provisional patents for small molecule discovery in immunology. He is currently enrolled in the High-Impact Cancer Research postgraduate certificate program at Harvard Medical School.

Joseph Lobacki


Joseph Lobacki has served on the Board of Directors of Venn Therapeutics since 2017. Currently the CEO of Artax Biopharma, he also serves on the Board of Directors for Experience Sutro Biopharma, Inc.


Mr. Lobacki’s career spans 30+ years in the pharmaceutical and biotech industries. He has an impressive track record of consistently delivering shareholder value while managing large and complex pharmaceutical divisions. Notably, Mr. Lobacki was the Chief Commercial Officer at Medivation prior to its $14B acquisition by Pfizer in 2016. He was also the Senior Vice President and General Manager for Genzyme’s transplant and oncology division, prior to its $20B acquisition by Sanofi in 2011.


Mr. Lobacki holds undergraduate degrees in biology from Boston College and in pharmacy from the Massachusetts College of Pharmacy.

Bruce Hrovat

Bruce Hrovat has served on the Board of Directors of Venn Therapeutics since 2016. He is a seasoned banking professional with 20 years of experience in retail, commercial, and wholesale banking, with expertise in intraday liquidity, governance, risk, and compliance.


Mr. Hrovat has designed future intraday liquidity risk management strategies and frameworks for some of the largest banks. As the CEO and President of INTRADAY, which provides the world's premier real-time treasury software, Mr. Hrovat implements intraday software solutions that free tens of millions of dollars annually.


Mr. Hrovat has served as the COO of a top 20 regional bank, and he drove nearly $400 billion of payments each day for a top 20 global transaction bank. Earlier in his career, he was responsible for driving a consistent customer experience across a network of 5,000+ Bank of America branches. 


Mr. Hrovat holds undergraduate degrees in economics and petroleum engineering from Marietta College. He has previously served on boards for The Clearing House (TCH) and Rhode Island Philharmonic Orchestra and Music School. TCH is the only private-sector ACH and wire operator in the United States, clearing and settling nearly $2 trillion in U.S. dollar payments each day, representing half of all commercial ACH and wire volume.

Howard Winston


Howard Winston has served as a member of our Board of Directors since 2016. Mr. Winston is a Partner at Montrose Capital Group, LLC, where he focuses on special situation investment opportunities, as well as advising family offices. Prior to forming Montrose he was a Principal at Waveland Capital Management, L.P., a Chicago based hedge fund where he was an investment analyst focused on publicly traded securities. 

Please reload

  • Venn Therapeutics on Twitter
  • Venn Therapeutics on LinkedIn